The immuno side of melanoma
16 Jul 2012
The immuno side of melanoma
Constructing successful biomarker clinical trials
Highlights of the 22nd EACR meeting and tackling glioblastoma
The changing field of drug development
Epigenetics of cancer and changes in DNA modification in tumours
Perifosine disappoints in refractory mCRC
Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment
Advances in radiotherapy for rectal cancer
A new direction for development of targeted cancer therapies
Application of next generation sequencing
Next generation sequencing and WIN therapeutics
Identifying targets with systems medicine